Practice guidelines for the management of cryptococcal disease

Clinical Infectious Diseases

Volumn 30, Issue 4, 2000, Pages 710-718

  Saag, Michael S ^a   Graybill, Richard J ^b   Larsen, Robert A ^c   Pappas, Peter G ^a   Perfect, John R ^d   Powderly, William G ^e   Sobel, Jack D ^f   Dismukes, William E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d DUKE UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; PYRROLE;

COMBINATION CHEMOTHERAPY; CRYPTOCOCCUS NEOFORMANS; DISEASE DURATION; DISEASE SEVERITY; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOCOMPETENCE; INTRACRANIAL PRESSURE; KIDNEY FUNCTION; LUNG MYCOSIS; MAINTENANCE THERAPY; MONOTHERAPY; MYCOTIC MENINGITIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; URINARY TRACT DISEASE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; COST-BENEFIT ANALYSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMAN; INTRACRANIAL PRESSURE; MENINGITIS, FUNGAL; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 0033801252     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313757     Document Type: Review

References (37)

1. A comparison of amphotericin B 717 alone and combined with flucytosine in the treatment of cryptococcal meningitis
2. 5-Fluorocytosine in human cryptococcosis
3. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks
4. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: Retrospective analysis of 83 cases
5. The evolution of pulmonary cryptococcosis: Clinical implications from a study of 41 patients with and without compromising host factors
6. Fluconazole monotherapy for cryptococcosis in non-AIDS patients
7. Cryptococcosis in HIV-negative patients: Analysis of 306 cases
8. Practice guidelines for the treatment of fungal infections
9. Itraconazole therapy for cryptococcal meningitis and cryptococcosis
10. Treatment of systemic mycoses with ketoconazole: Emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases Collaborative Antifungal Study
11. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
12. Liposoma amphotericin B (Ambisome) compared with amphotericin B followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
13. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
14. Intraventricular therapy of cryptococcal meningitis via a subcutaneous reservoir
15. Treatment of nonmeningeal cryptococcal disease in HIV-infected persons
16. Fluconazole combined with flucytosine for cryptococcal meningitis in persons with AIDS
17. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
18. Fluconazole compared with amphotericin B plus flucytosine for the treatment of cryptococcal meningitis in AIDS: A randomized trial
19. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS
20. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis
21. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome
22. Cerebrospinal fluid hypertension patients with AIDS and cryptococcal meningitis
23. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome
24. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome
25. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
26. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 cells per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
27. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
28. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS
29. Cryptococcal meningitis: Outcome in patients with AIDS and patients with neoplastic disease
30. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome
31. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of AIDS-associated cryptococcal meningitis
32. Cryptococcal meningitis and AIDS
33. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis
34. Utility of serum and CSF cryptococcal antigen in the management of cryptococcal meningitis in AIDS patients [abstract 334]
35. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
36. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS
37. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS